On this Rare Disease Day, learn more about how biosimilars are poised to help treat patients with rare diseases.
On this Rare Disease Day, learn more about how biosimilars are poised to help treat patients with rare diseases.
Samsung Bioepis' Eculizumab Biosimilar Approved in Europe
May 31st 2023The European Commission has granted marketing authorization to Samsung Bioepis' biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, is the first hematology biosimilar from Samsung Bioepis to be approved in the European Union.
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points
August 24th 2022Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.